Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter

被引：6
作者：
Businello, Gianluca [1 ]
Angerilli, Valentina [1 ]
Lonardi, Sara [2 ]
Bergamo, Francesca [2 ]
Valmasoni, Michele [3 ]
Farinati, Fabio [3 ]
Savarino, Edoardo [3 ]
Spolverato, Gaya [3 ]
Fassan, Matteo [1 ,2 ]
机构：
[1] Univ Padua, Dept Med DIMED, Padua, Italy
[2] Ist Ricovero & Cura Carattere Sci IRCCS, Veneto Inst Oncol, Padua, Italy
[3] Univ Padua, Dept Surg Oncol & Gastroenterol DISCOG, Padua, Italy
来源：
UPDATES IN SURGERY | 2023年 / 75卷 / 02期
关键词：
Gastric adenocarcinoma; Gastroesophageal junction adenocarcinoma; Biomarkers; Immunohistochemistry; ADVANCED GASTRIC-CANCER; TYROSINE KINASE INHIBITOR; FGFR2 GENE AMPLIFICATION; DOUBLE-BLIND; OPEN-LABEL; 1ST-LINE THERAPY; HER2; STATUS; PHASE-II; MICROSATELLITE INSTABILITY; GASTROESOPHAGEAL CANCER;
D O I：
10.1007/s13304-022-01330-5
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
The comprehensive molecular characterization of gastric and gastroesophageal junction adenocarcinomas has led to the improvement of targeted and more effective treatments. As a result, several biomarkers have been introduced into clinical practice and the implementation of innovative diagnostic tools is under study. Such assessments are mainly based on the evaluation of limited biopsy material in clinical practice. In this setting, the pathologist represents a key player in the selection of patients facilitating precision medicine approaches.
引用
收藏
页码：291 / 303
页数：13
相关论文
共 50 条
  • [41] Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial
    Verschoor, Yara L.
    van de Haar, Joris
    van den Berg, Jose G.
    van Sandick, Johanna W.
    Kodach, Liudmila L.
    van Dieren, Jolanda M.
    Balduzzi, Sara
    Grootscholten, Cecile
    Ijsselsteijn, Marieke E.
    Veenhof, Alexander A. F. A.
    Hartemink, Koen J.
    Vollebergh, Marieke A.
    Jurdi, Adham
    Sharma, Shruti
    Spickard, Erik
    Owers, Emilia C.
    Bartels-Rutten, Annemarieke
    den Hartog, Peggy
    de Miranda, Noel F. C. C.
    van Leerdam, Monique E.
    Haanen, John B. A. G.
    Schumacher, Ton N.
    Voest, Emile E.
    Chalabi, Myriam
    NATURE MEDICINE, 2024, 30 (2) : 519 - 530
  • [42] Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction
    Richards, D.
    McCollum, D.
    Wilfong, L.
    Sborov, M.
    Boehm, K. A.
    Zhan, F.
    Asmar, L.
    ANNALS OF ONCOLOGY, 2008, 19 (01) : 104 - 108
  • [43] Toxicity profiles of immunochemotherapy for gastric or gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis
    Wan, Linghong
    Tian, Fanxuan
    Wang, Lei
    Hou, Yongying
    Liu, Wenkang
    Liu, Qin
    Chen, Dongfeng
    Li, Xianfeng
    Xiang, Junyv
    Qin, Zhong-Yi
    Wang, Tao
    Mao, Bijng
    Wu, Linyu
    Hu, Lu
    CELLULAR ONCOLOGY, 2024, : 2335 - 2347
  • [44] Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers
    Wainberg, Zev A.
    Soares, Heloisa P.
    Patel, Ravi
    DiCarlo, Brian
    Park, David J.
    Liem, Andre
    Wang, He-jing
    Yonemoto, Lisa
    Martinez, Diego
    Laux, Isett
    Brennan, Meghan
    Hecht, J. Randolph
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (01) : 61 - 67
  • [45] Predicting Response to Treatment in Gastroesophageal Junction Adenocarcinomas: Combining Clinical, Imaging, and Molecular Biomarkers
    Bain, Gillian H.
    Petty, Russell D.
    ONCOLOGIST, 2010, 15 (03) : 270 - 284
  • [46] Does radiomics play a role in the diagnosis, staging and re-staging of gastroesophageal junction adenocarcinoma?
    Mori, Martina
    Palumbo, Diego
    De Cobelli, Francesco
    Fiorino, Claudio
    UPDATES IN SURGERY, 2023, 75 (02) : 273 - 279
  • [47] Does radiomics play a role in the diagnosis, staging and re-staging of gastroesophageal junction adenocarcinoma?
    Martina Mori
    Diego Palumbo
    Francesco De Cobelli
    Claudio Fiorino
    Updates in Surgery, 2023, 75 : 273 - 279
  • [48] Costs of Trastuzumab in Combination With Chemotherapy for HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: An Economic Evaluation in the Chinese Context
    Wu, Bin
    Ye, Ming
    Chen, Huafeng
    Shen, Jinfang F.
    CLINICAL THERAPEUTICS, 2012, 34 (02) : 468 - 479
  • [49] Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma
    Zhang, Yang
    Qiu, Miao-Zhen
    Wang, Ju-Feng
    Zhang, Yan-Qiao
    Shen, Ao
    Yuan, Xiang-Lin
    Zhang, Tao
    Wei, Xiao-Li
    Zhao, Hong-Yun
    Wang, De-Shen
    Zhao, Qi
    Xiong, Gao-Zhun
    Ji, Yan-Ping
    Liang, Xue-Jun
    Xia, Gang
    Xu, Rui-Hua
    CELL REPORTS MEDICINE, 2022, 3 (11)
  • [50] Prognostic implications of visceral obesity on gastric adenocarcinoma: does it really matter?
    Coruh, Aysegul Gursoy
    Uzun, Caglar
    Akkaya, Zehra
    Avci, Orhan
    Adiuguzel, Mehmet
    Ersoz, Cevriye Cansiz
    Elhan, Atilla Halil
    CLINICAL IMAGING, 2021, 76 (76) : 228 - 234
12345